目的 觀察清咳平喘顆粒治療輕型、中型新冠病毒感染患者的臨床有效性及安全性。方法 選取2023年4月—2023年6月在常州市第三人民醫(yī)院就診的輕型、中型新冠病毒感染（痰熱壅肺型）患者93例，按照隨機(jī)數(shù)字表法將患者分為對照組（45例）和治療組（48例）。對照組患者進(jìn)行基礎(chǔ)治療及抗病毒治療。治療組在對照組治療基礎(chǔ)上服用清咳平喘顆粒，1袋/次，3次/d，兩組療程均為7 d。觀察兩組患者臨床療效，比較治療前后兩組患者中醫(yī)證候評分，簡易咳嗽程度評分表（CET），主要臨床癥狀消失率及C反應(yīng)尿蛋白（CRP）、降鈣素原（PCT）、白細(xì)胞介素-6（IL-6）等炎癥指標(biāo)。結(jié)果 治療后，治療組總有效率（97.92%）顯著高于對照組（86.67%）（P＜0.05）。治療后，兩組中醫(yī)證候評分、咳嗽程度評分顯著降低（P＜0.05），且治療組在第7天的治療作用顯著強(qiáng)于對照組（P＜0.05）。治療后，相比對照組，治療組能夠顯著促進(jìn)咳嗽癥狀消失（P＜0.05）。治療后，兩組患者炎癥指標(biāo)IL-6、CRP水平顯著降低（P＜0.05），且治療組顯著低于對照組（P＜0.05）。結(jié)論 清咳平喘顆粒聯(lián)合西醫(yī)常規(guī)治療能夠顯著提高新冠病毒感染治療的臨床有效率，降低中醫(yī)證候評分，改善患者咳嗽程度，促進(jìn)咳嗽癥狀的緩解與消失，降低炎癥水平，安全性良好，具有臨床推廣價值。

Objective To observe the clinical efficacy and safety of Qingke Pingchuan Granules in treatment of patients with mild and moderate COVID-19 infection. Methods Patients (93 cases) with mild and moderate COVID-19 infection in Changzhou Third People’s Hospital from April 2023 to June 2023 were randomly divided into control (45 cases) and treatment (48 cases) group. Patients in the control group was treated with western medicine, and the basic treatment and antiviral treatment were carried out according to COVID-19’s diagnosis and treatment plan (trial version 10). Patients in the treatment group were po administered with Qingke Pingchuan Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluations were evaluated, the TCM syndrome scores, cough severity scores, the disappearance rate of major clinical symptoms, and inflammatory indicators in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.92%) was significantly higher than that of the control group (86.67%, P < 0.05). After treatment, the scores of TCM syndrome and cough degree in two groups were significantly decreased (P< 0.05), and the therapeutic effect of the treatment group on the 7th day was significantly stronger than that of the control group (P < 0.05). After treatment, compared with the control group, the treatment group could significantly promote the disappearance of cough symptoms (P < 0.05). After treatment, the levels of inflammatory indexes IL-6 and CRP in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Qingke Pingchuan Granules in treatment of patients with mild and moderate COVID-19 infection can significantly improve the clinical effective rate, reduce the TCM syndrome score, improve the degree of cough, promote the relief and disappearance of cough symptoms, and reduce the level of inflammation, which has good safety and clinical popularization value.

R974